{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:36Z","timestamp":1781632356119,"version":"3.54.5"},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T00:00:00Z","timestamp":1242000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bryostatin 1, isolated from a marine bryozoan, enhances the efficacy of cytotoxic agents through modulation of the protein kinase C pathway and is active in combination with vincristine for diffuse large B\u2010cell lymphoma. Further, the apoptotic frequency of peripheral blood T lymphocytes as determined by flow cytometry may predict which patients will respond to this combination. We tested the efficacy and safety of bryostatin 1 50 \u03bcg\/m<jats:sup>2<\/jats:sup> given over 24 hr and vincristine 1.4 mg\/m<jats:sup>2<\/jats:sup> on days 1 and 15 every 28 days in aggressive B\u2010cell non\u2010Hodgkin lymphoma (NHL) relapsing after autologous stem cell transplantation. End points included tumor response, toxicity, and survival. Responses were correlated with an increase in apoptotic frequency of CD5+ cells by flow cytometry using annexin V staining. Fourteen patients were enrolled with 13 being evaluable for a response. The overall response rate was 31% with two patients achieving a complete response. The most common toxicities were Grade 3 lymphopenia (seven patients), Grade 3 to 4 neutropenia (two patients), and Grade 3 hypophosphatemia (two patients). Median progression\u2010free and overall survivals for all patients were 5.7 and 21.4 months, respectively. One patient demonstrated an increase in T\u2010cell apoptotic frequency, also achieving a complete response. Bryostatin 1 and vincristine have efficacy in select patients with aggressive NHL. Future investigations of agents targeting the protein kinase C pathway may benefit from early response assessment using flow cytometry to evaluate T\u2010cell apoptosis. Am. J. Hematol., 2009. \u00a9 2009 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21449","type":"journal-article","created":{"date-parts":[[2009,5,11]],"date-time":"2009-05-11T18:25:32Z","timestamp":1242066332000},"page":"484-487","source":"Crossref","is-referenced-by-count":55,"title":["Phase II study of bryostatin 1 and vincristine for aggressive non\u2010Hodgkin lymphoma relapsing after an autologous stem cell transplant"],"prefix":"10.1002","volume":"84","author":[{"given":"Paul M.","family":"Barr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Schluchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Panneerselvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Jacobberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalini","family":"Janakiraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Simic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scot C.","family":"Remick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,6,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.023"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(85)90205-0"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.23.8483"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(87)90239-4"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood.V74.5.1747.1747","article-title":"Bryostatin 1 induces differentiation of B\u2010chronic lymphocytic leukemia cells","volume":"74","author":"Drexler HG","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb07941.x"},{"key":"e_1_2_1_9_2","first-page":"2810","article-title":"In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity","volume":"53","author":"Berkow RL","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01525985"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood.V89.9.3402","article-title":"The antineoplastic agent bryostatin\u20101 induces proinflammatory cytokine production in human monocytes: Synergy with interleukin\u20102 and modulation of interleukin\u20102Rgamma chain expression","volume":"89","author":"Bosco MC","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.22.1812"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.352"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.356"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.1.4.17"},{"key":"e_1_2_1_16_2","first-page":"825","article-title":"Phase II trial of bryostatin 1 in patients with relapsed low\u2010grade non\u2010Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"6","author":"Varterasian ML","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1624"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900080203"},{"key":"e_1_2_1_19_2","first-page":"101","article-title":"Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity","volume":"52","author":"Hornung RL","year":"1992","journal-title":"Cancer Res"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(93)90134-7"},{"key":"e_1_2_1_21_2","first-page":"165","article-title":"Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents","volume":"54","author":"Mohammad RM","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_1_22_2","first-page":"4950","article-title":"The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP\u2010resistant human diffuse large Cell lymphoma xenograft model","volume":"6","author":"Mohammad RM","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2739"},{"key":"e_1_2_1_24_2","first-page":"83","article-title":"Protein kinase C\u2010dependent activation of the tumor necrosis factor receptor\u2010mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol","volume":"2","author":"Cartee L","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_1_25_2","first-page":"1305","article-title":"Bryostatin 1 down\u2010regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts","volume":"4","author":"Al\u2010Katib AM","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(95)00037-O"},{"key":"e_1_2_1_27_2","first-page":"5929","article-title":"Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B\u2010cell malignancies","volume":"9","author":"Dowlati A","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja8015632"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2730"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.7859"},{"key":"e_1_2_1_31_2","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood.V110.11.2619.2619","article-title":"Modulation of CD20 expression in rituximab\u2010sensitive (RSCL) and rituximab resistant cell lines (RRCL) using IL\u20104 and bryostatin\u20101","volume":"110","author":"Tsai P\u2010C","year":"2007","journal-title":"Blood"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_1_33_2","first-page":"521","volume-title":"Cancer: Principles and Practice of Oncology","author":"Simon R","year":"2001"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21449","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:51:53Z","timestamp":1700067113000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,17]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1002\/ajh.21449"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21449","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,17]]}}}